The Long and Winding Road of Vagus Nerve Stimulation: Challenges in Developing an Intervention for Difficult-to-Treat Mood Disorders

References

• George MS, Sackeim HA. Brain stimulation, revolutions, and the shifting time domain of depression. Biol Psychiatry. 2008;64(6):447–448. doi:10.1016/j.biopsych.2008.07.01318724998
   PubMed Web of Science ®Google Scholar
• Perera T, George MS, Grammer G, Janicak PG, Pascual-Leone A, Wirecki TS. The clinical TMS society consensus review and treatment recommendations for TMS therapy for major depressive disorder. Brain Stimul. 2016;9(3):336–346. doi:10.1016/j.brs.2016.03.01027090022
   PubMed Web of Science ®Google Scholar
• Mutz J, Vipulananthan V, Carter B, Hurlemann R, Fu CHY, Young AH. Comparative efficacy and acceptability of non-surgical brain stimulation for the acute treatment of major depressive episodes in adults: systematic review and network meta-analysis. BMJ. 2019;364:l1079. doi:10.1136/bmj.l107930917990
   PubMed Web of Science ®Google Scholar
• McClintock SM, Reti IM, Carpenter LL, et al. Consensus recommendations for the clinical application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of depression. J Clin Psychiatry. 2018;79(1):35–48. doi:10.4088/JCP.16cs10905
   Web of Science ®Google Scholar
• Carpenter LL, Janicak PG, Aaronson ST, et al. Transcranial magnetic stimulation (TMS) for major depression: a multisite, naturalistic, observational study of acute treatment outcomes in clinical practice. Depress Anxiety. 2012;29(7):587–596. doi:10.1002/da.2196922689344
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Aaronson ST, Carpenter LL, et al. Clinical outcomes in a large registry of patients with major depressive disorder treated with transcranial magnetic stimulation. J Affect Disord. 2020;277:65–74. doi:10.1016/j.jad.2020.08.00532799106
   PubMed Web of Science ®Google Scholar
• Sackeim HA. Modern electroconvulsive therapy: vastly improved yet greatly underused. JAMA Psychiatry. 2017;74(8):779–780. doi:10.1001/jamapsychiatry.2017.167028658461
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Lux L, Gartlehner G, et al. Defining treatment-resistant depression. Depress Anxiety. 2020;37(2):134–145. doi:10.1002/da.2296831638723
   PubMed Web of Science ®Google Scholar
• Rush AJ, Aaronson ST, Demyttenaere K. Difficult-to-treat depression: a clinical and research roadmap for when remission is elusive. Aust N Z J Psychiatry. 2019;53(2):109–118. doi:10.1177/000486741880858530378447
   PubMed Web of Science ®Google Scholar
• McAllister-Williams RH, Arango C, Blier P, et al. The identification, assessment and management of difficult-to-treat depression: an international consensus statement. J Affect Disord. 2020;267:264–282. doi:10.1016/j.jad.2020.02.02332217227
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine: Health and Medicine Division: Food and Nutrition Board: Committee on the Development of Guiding Principles for the Inclusion of Chronic Disease Endpoints in Future Dietary Reference Intakes. Measuring chronic disease outcomesIn: Oria M, Kumanyika S, editors. Guiding Principles for Developing Dietary Reference Intakes Based on Chronic Disease. National Academies Press (US); 2017.
   Google Scholar
• Working Group on Health Outcomes for Older Persons with Multiple Chronic Conditions. Universal health outcome measures for older persons with multiple chronic conditions. J Am Geriatr Soc. 2012;60(12):2333–2341. doi:10.1111/j.1532-5415.2012.04240.x.23194184
   PubMed Web of Science ®Google Scholar
• Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ. Chronic vagus nerve stimulation significantly improves quality of life in treatment-resistant major depression. J Clin Psychiatry. 2018;79(5). doi:10.4088/JCP.18m12178
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Summary of safety and effectiveness data (SSED) for vagus nerve stimulation in depression; 7 13, 2020 [ updated June 15, 2005]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/p970003s207b.pdf. Accessed 1130, 2020.
   Google Scholar
• Rush AJ, Marangell LB, Sackeim HA, et al. Vagus nerve stimulation for treatment-resistant depression: a randomized, controlled acute phase trial. Biol Psychiatry. 2005;58(5):347–354. doi:10.1016/j.biopsych.2005.05.02516139580
   PubMed Web of Science ®Google Scholar
• Rush AJ, George MS, Sackeim HA, et al. Vagus nerve stimulation (VNS) for treatment-resistant depressions: a multicenter study. Biol Psychiatry. 2000;47(4):276–286. doi:10.1016/s0006-3223(99)00304-210686262
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Rush AJ, George MS, et al. Vagus nerve stimulation (VNS) for treatment-resistant depression: efficacy, side effects, and predictors of outcome. Neuropsychopharmacology. 2001;25(5):713–728. doi:10.1016/S0893-133X(01)00271-811682255
   PubMed Web of Science ®Google Scholar
• Aaronson ST, Sears P, Ruvuna F, et al. A 5-year observational study of patients With treatment-resistant depression treated with vagus nerve stimulation or treatment as usual: comparison of response, remission, and suicidality. Am J Psychiatry. 2017;174(7):640–648. doi:10.1176/appi.ajp.2017.1601003428359201
   PubMed Web of Science ®Google Scholar
• Bottomley JM, LeReun C, Diamantopoulos A, Mitchell S, Gaynes BN. Vagus nerve stimulation (VNS) therapy in patients with treatment resistant depression: a systematic review and meta-analysis. Compr Psychiatry. 2020;98:152–156. doi:10.1016/j.comppsych.2019.152156
   Web of Science ®Google Scholar
• Berry SM, Broglio K, Bunker M, Jayewardene A, Olin B, Rush AJ. A patient-level meta-analysis of studies evaluating vagus nerve stimulation therapy for treatment-resistant depression. Med Devices (Auckl). 2013;6:17–35. doi:10.2147/MDER.S4101723482508
   PubMedGoogle Scholar
• Trottier-Duclos F, Desbeaumes Jodoin V, Fournier-Gosselin MP, et al. A 6-year follow-up study of vagus nerve stimulation effect on quality of life in treatment-resistant depression: a pilot study. J ECT. 2018;34(4):e58–e60. doi:10.1097/YCT.000000000000048529424758
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Brannan SK, Rush AJ, George MS, Marangell LB, Allen J. Durability of antidepressant response to vagus nerve stimulation (VNS). Int J Neuropsychopharmacol. 2007;10(6):817–826. doi:10.1017/S146114570600742517288644
   PubMed Web of Science ®Google Scholar
• Nahas Z, Marangell LB, Husain MM, et al. Two-year outcome of vagus nerve stimulation (VNS) for treatment of major depressive episodes. J Clin Psychiatry. 2005;66(9):1097–1104. doi:10.4088/jcp.v66n090216187765
   PubMed Web of Science ®Google Scholar
• Kumar A, Bunker MT, Aaronson ST, et al. Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. Neuropsychiatr Dis Treat. 2019;15:457–468. doi:10.2147/NDT.S19666530858703
   PubMed Web of Science ®Google Scholar
• Yap JYY, Keatch C, Lambert E, Woods W, Stoddart PR, Kameneva T. Critical review of transcutaneous vagus nerve stimulation: challenges for translation to clinical practice. Review. Front Neurosci. 2020;14(284). doi:10.3389/fnins.2020.00284
   Web of Science ®Google Scholar
• Kaniusas E, Kampusch S, Tittgemeyer M, et al. Current directions in the auricular vagus nerve stimulation i – a physiological perspective. Review. Front Neurosci. 2019;13(854). doi:10.3389/fnins.2019.00854
   Web of Science ®Google Scholar
• Hein E, Nowak M, Kiess O, et al. Auricular transcutaneous electrical nerve stimulation in depressed patients: a randomized controlled pilot study. J Neural Transm. 2013;120(5):821–827. doi:10.1007/s00702-012-0908-623117749
   PubMed Web of Science ®Google Scholar
• Fang J, Rong P, Hong Y, et al. Transcutaneous vagus nerve stimulation modulates default mode network in major depressive disorder. Biol Psychiatry. 2016;79(4):266–273. doi:10.1016/j.biopsych.2015.03.02525963932
   PubMed Web of Science ®Google Scholar
• Rong P, Liu J, Wang L, et al. Effect of transcutaneous auricular vagus nerve stimulation on major depressive disorder: a nonrandomized controlled pilot study. J Affect Disord. 2016;195:172–179. doi:10.1016/j.jad.2016.02.03126896810
   PubMed Web of Science ®Google Scholar
• Trevizol AP, Shiozawa P, Taiar I, et al. Transcutaneous vagus nerve stimulation (taVNS) for major depressive disorder: an open label proof-of-concept trial. Brain Stimul. 2016;9(3):453–454. doi:10.1016/j.brs.2016.02.00126944188
   PubMed Web of Science ®Google Scholar
• Woodbury DM, Woodbury JW. Effects of vagal stimulation on experimentally induced seizures in rats. Epilepsia. 1990;31(Suppl 2):S7–S19. doi:10.1111/j.1528-1157.1990.tb05852.x2226368
   PubMed Web of Science ®Google Scholar
• Zabara J. Inhibition of experimental seizures in canines by repetitive vagal stimulation. Epilepsia. 1992;33(6):1005–1012. doi:10.1111/j.1528-1157.1992.tb01751.x1464256
   PubMed Web of Science ®Google Scholar
• The Vagus Nerve Stimulation Study Group. A randomized controlled trial of chronic vagus nerve stimulation for treatment of medically intractable seizures. Neurology. 1995;45(2):224–230. doi:10.1212/wnl.45.2.224.7854516
   PubMed Web of Science ®Google Scholar
• Handforth A, DeGiorgio CM, Schachter SC, et al. Vagus nerve stimulation therapy for partial-onset seizures: a randomized active-control trial. Neurology. 1998;51(1):48–55. doi:10.1212/wnl.51.1.489674777
   PubMed Web of Science ®Google Scholar
• Morris GL 3rd, Mueller WM. Long-term treatment with vagus nerve stimulation in patients with refractory epilepsy. The Vagus Nerve Stimulation Study Group E01-E05. Neurology. 1999;53(8):1731–1735. doi:10.1212/wnl.53.8.173110563620
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Decina P, Prohovnik I, Malitz S, Resor SR. Anticonvulsant and antidepressant properties of electroconvulsive therapy: a proposed mechanism of action. Biol Psychiatry. 1983;18(11):1301–1310.6317065
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The anticonvulsant hypothesis of the mechanisms of action of ECT: current status. J ECT. 1999;15(1):5–26. doi:10.1097/00124509-199903000-0000310189616
   PubMed Web of Science ®Google Scholar
• Seymour J. Commentary and update on the contribution of the GABA hypothesis to understanding the mechanism of action of electroconvulsive therapy. J ECT. 2020. doi:10.1097/YCT.0000000000000711
   Web of Science ®Google Scholar
• Dunn R, Frye M, Kimbrell T, Denicoff K, Leverich G, Post R. The efficacy and use of anticonvulsants in mood disorders. Clin Neuropharmacol. 1998;21(4):215–235.9704164
   PubMed Web of Science ®Google Scholar
• Reinares M, Rosa AR, Franco C, et al. A systematic review on the role of anticonvulsants in the treatment of acute bipolar depression. Int J Neuropsychopharmacol. 2012;16(2):485–496. doi:10.1017/s146114571200049122575611
   PubMed Web of Science ®Google Scholar
• Adair D, Truong D, Esmaeilpour Z, et al. Electrical stimulation of cranial nerves in cognition and disease. Brain Stimul. 2020;13(3):717–750. doi:10.1016/j.brs.2020.02.01932289703
   PubMed Web of Science ®Google Scholar
• Thompson N, Mastitskaya S, Holder D. Avoiding off-target effects in electrical stimulation of the cervical vagus nerve: neuroanatomical tracing techniques to study fascicular anatomy of the vagus nerve. J Neurosci Methods. 2019;325:108325. doi:10.1016/j.jneumeth.2019.10832531260728
   PubMed Web of Science ®Google Scholar
• Cottle MKW, Calaresu FR. Projections from the nucleus and tractus solitarius in the cat. J Comp Neurol. 1975;161(2):143–157. doi:10.1002/cne.9016102021127142
   PubMed Web of Science ®Google Scholar
• Ricardo JA, Tongju Koh E. Anatomical evidence of direct projections from the nucleus of the solitary tract to the hypothalamus, amygdala, and other forebrain structures in the rat. Brain Res. 1978;153(1):1–26. doi:10.1016/0006-8993(78)91125-3679038
   PubMed Web of Science ®Google Scholar
• Krahl SE, Senanayake SS, Pekary AE, Sattin A. Vagus nerve stimulation (VNS) is effective in a rat model of antidepressant action. J Psychiatr Res. 2004;38(3):237–240. doi:10.1016/j.jpsychires.2003.11.00515003428
   PubMed Web of Science ®Google Scholar
• Elger G, Hoppe C, Falkai P, Rush AJ, Elger CE. Vagus nerve stimulation is associated with mood improvements in epilepsy patients. Epilepsy Res. 2000;42(2–3):203–210. doi:10.1016/s0920-1211(00)00181-911074193
   PubMed Web of Science ®Google Scholar
• Sackeim HA. The definition and meaning of treatment-resistant depression. J Clin Psychiatry. 2001;62(Suppl 16):10–17.
   PubMedGoogle Scholar
• Sackeim HA, Aaronson ST, Bunker MT, et al. The assessment of resistance to antidepressant treatment: rationale for the antidepressant treatment history form: short form (ATHF-SF). J Psychiatr Res. 2019;113:125–136. doi:10.1016/j.jpsychires.2019.03.02130974339
   PubMed Web of Science ®Google Scholar
• Schlaepfer TE, Frick C, Zobel A, et al. Vagus nerve stimulation for depression: efficacy and safety in a European study. Psychol Med. 2008;38(5):651–661. doi:10.1017/S003329170700192418177525
   PubMed Web of Science ®Google Scholar
• Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010;30(3):273–281. doi:10.1097/JCP.0b013e3181db883120473062
   PubMed Web of Science ®Google Scholar
• George MS, Rush AJ, Marangell LB, et al. A one-year comparison of vagus nerve stimulation with treatment as usual for treatment-resistant depression. Biol Psychiatry. 2005;58(5):364–373. doi:10.1016/j.biopsych.2005.07.02816139582
   PubMed Web of Science ®Google Scholar
• Rush AJ, Sackeim HA, Marangell LB, et al. Effects of 12 months of vagus nerve stimulation in treatment-resistant depression: a naturalistic study. Biol Psychiatry. 2005;58(5):355–363. doi:10.1016/j.biopsych.2005.05.02416139581
   PubMed Web of Science ®Google Scholar
• Depression Guideline Panel. Depression in primary care: Vol.2. Treatment of major depression. U.S. Department of Health and Human Services, Public Health Service, Agency for Health Care Policy and Research, AHCPR. No. 93-0551; 1993.
   Google Scholar
• Labiner DM, Ahern GL. Vagus nerve stimulation therapy in depression and epilepsy: therapeutic parameter settings. Acta Neurol Scand. 2007;115(1):23–33. doi:10.1111/j.1600-0404.2006.00732.x17156262
   PubMed Web of Science ®Google Scholar
• Rush AJ, Gullion CM, Basco MR, Jarrett RB, Trivedi MH. The Inventory of Depressive Symptomatology (IDS): psychometric properties. Psychol Med. 1996;26(3):477–486. doi:10.1017/S00332917000355588733206
   PubMed Web of Science ®Google Scholar
• Montgomery SA, Åsberg M. A new depression scale designed to be sensitive to change. Br J Psychiatry. 1979;134:382–389. doi:10.1192/bjp.134.4.382444788
   PubMed Web of Science ®Google Scholar
• Guy W ECDEU assessment manual for psychopharmacology. Superintendent of Documents, U.S. Government Printing Office, U.S. Department of Health, Education, and Welfare Publication, No. 76-338; 1976.
   Google Scholar
• Dunner DL, Rush AJ, Russell JM, et al. Prospective, long-term, multicenter study of the naturalistic outcomes of patients with treatment-resistant depression. J Clin Psychiatry. 2006;67(5):688–695. doi:10.4088/JCP.v67n050116841617
   PubMed Web of Science ®Google Scholar
• Post RM, Uhde TW, Rubinow DR, Huggins T. Differential time course of antidepressant effects after sleep deprivation, ECT, and carbamazepine: clinical and theoretical implications. Psychiatry Res. 1987;22(1):11–19. doi:10.1016/0165-1781(87)90045-X3659217
   PubMed Web of Science ®Google Scholar
• Roy-Byrne PP, Uhde TW, Post RM. Effects of one night’s sleep deprivation on mood and behavior in panic disorder. Patients with panic disorder compared with depressed patients and normal controls. Arch Gen Psychiatry. 1986;43(9):895–899. doi:10.1001/archpsyc.1986.018000900850113753167
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905–1917. doi:10.1176/ajp.2006.163.11.190517074942
   PubMed Web of Science ®Google Scholar
• Conway CR, George MS, Sackeim HA. Towards an evidence-based, operational definition of treatment-resistant depression: when enough is enough. JAMA Psychiatry. 2017;74(1):9–10. doi:10.1001/jamapsychiatry.2016.258627784055
   PubMed Web of Science ®Google Scholar
• Prudic J, Haskett RF, Mulsant B, et al. Resistance to antidepressant medications and short-term clinical response to ECT. Am J Psychiatry. 1996;153(8):985–992.8678194
   PubMed Web of Science ®Google Scholar
• Prudic J, Sackeim HA, Devanand DP. Medication resistance and clinical response to electroconvulsive therapy. Psychiatry Res. 1990;31(3):287–296. doi:10.1016/0165-1781(90)90098-P1970656
   PubMed Web of Science ®Google Scholar
• Heijnen WT, Birkenhager TK, Wierdsma AI, van den Broek WW. Antidepressant pharmacotherapy failure and response to subsequent electroconvulsive therapy: a meta-analysis. J Clin Psychopharmacol. 2010;30(5):616–619. doi:10.1097/JCP.0b013e3181ee0f5f20814336
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Devanand DP, Decina P, Kerr B, Malitz S. The impact of medication resistance and continuation pharmacotherapy on relapse following response to electroconvulsive therapy in major depression. J Clin Psychopharmacol. 1990;10(2):96–104. doi:10.1097/00004714-199004000-000042341598
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Devanand DP, et al. A prospective, randomized, double-blind comparison of bilateral and right unilateral electroconvulsive therapy at different stimulus intensities. Arch Gen Psychiatry. 2000;57(5):425–434. doi:10.1001/archpsyc.57.5.42510807482
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Haskett RF, Mulsant BH, et al. Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. JAMA. 2001;285(10):1299–1307. doi:10.1001/jama.285.10.129911255384
   PubMed Web of Science ®Google Scholar
• Prudic J, Haskett RF, McCall WV, et al. Pharmacological strategies in the prevention of relapse after electroconvulsive therapy. J ECT. 2013;29(1):3–12. doi:10.1097/YCT.0b013e31826ea8c423303417
   PubMed Web of Science ®Google Scholar
• Sackeim HA. Acute, continuation and maintenance treatment of major depressive episodes with Transcranial Magnetic Stimulation. Brain Stimul. 2016;9(3):313–319. doi:10.1016/j.brs.2016.03.00627052475
   PubMed Web of Science ®Google Scholar
• Schultz D VNS therapy system PMA approval for chronic or recurrent depression. FDA. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf/P970003S050a.pdf. Accessed 1130, 2020.
   Google Scholar
• Centers for Medicare and Medicaid Services. National coverage determination (NCD) for vagus nerve stimulation (VNS) (160.18). CMS; 2007 Available from: https://www.cms.gov/Regulations-and-Guidance/Guidance/Transmittals/Downloads/R70NCD.pdf. Accessed 1130, 2020.
   Google Scholar
• NICE (National Institue for Health and Clinical Excellence). Implanted vagus nerve stimulation for treatment-resistant depression (IPG679). National Clinical Practice Guideline. NICE; 2020.
   Google Scholar
• ANZHSN (Australai and New Zealand Horizon Scanning Network). National Horizon Scanning Unit Horizon Scanning Prioritising Summary: Update Number 3, VNS Therapy System for the Treatment of Depression. Adelaide Health Technology Assessment; 2007.
   Google Scholar
• Aaronson ST, Carpenter LL, Conway CR, et al. Vagus nerve stimulation therapy randomized to different amounts of electrical charge for treatment-resistant depression: acute and chronic effects. Brain Stimul. 2013;6(4):631–640. doi:10.1016/j.brs.2012.09.01323122916
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Devanand DP, et al. Effects of stimulus intensity and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. N Engl J Med. 1993;328(12):839–846. doi:10.1056/NEJM1993032532812048441428
   PubMed Web of Science ®Google Scholar
• McCall WV, Reboussin DM, Weiner RD, Sackeim HA. Titrated moderately suprathreshold vs fixed high-dose right unilateral electroconvulsive therapy: acute antidepressant and cognitive effects. Arch Gen Psychiatry. 2000;57(5):438–444. doi:10.1001/archpsyc.57.5.43810807483
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Prudic J, Nobler MS, et al. Effects of pulse width and electrode placement on the efficacy and cognitive effects of electroconvulsive therapy. Brain Stimul. 2008;1(2):71–83. doi:10.1016/j.brs.2008.03.00119756236
   PubMed Web of Science ®Google Scholar
• Panebianco M, Rigby A, Weston J, Marson AG. Vagus nerve stimulation for partial seizures. Cochrane Database Syst Rev. 2015;4:CD002896. doi:10.1002/14651858.CD002896.pub2
   Web of Science ®Google Scholar
• O’Reardon JP, Solvason HB, Janicak PG, et al. Efficacy and safety of transcranial magnetic stimulation in the acute treatment of major depression: a multisite randomized controlled trial. Biol Psychiatry. 2007;62(11):1208–1216. doi:10.1016/j.biopsych.2007.01.01817573044
   PubMed Web of Science ®Google Scholar
• George MS, Lisanby SH, Avery D, et al. Daily left prefrontal transcranial magnetic stimulation therapy for major depressive disorder: a sham-controlled randomized trial. Arch Gen Psychiatry. 2010;67(5):507–516. doi:10.1001/archgenpsychiatry.2010.4620439832
   PubMed Web of Science ®Google Scholar
• Sackeim HA, Decina P, Prohovnik I, Malitz S. Seizure threshold in electroconvulsive therapy. Effects of sex, age, electrode placement, and number of treatments. Arch Gen Psychiatry. 1987;44(4):355–360. doi:10.1001/archpsyc.1987.018001600670093566457
   PubMed Web of Science ®Google Scholar
• American Psychiatric Association. The Practice of ECT: Recommendations for Treatment, Training and Privileging. Second Edition. American Psychiatric Press; 2001.
   Google Scholar
• Martin JLR, Martín-Sánchez E. Systematic review and meta-analysis of vagus nerve stimulation in the treatment of depression: variable results based on study designs. Eur Psychiatry. 2012;27(3):147–155. doi:10.1016/j.eurpsy.2011.07.00622137776
   PubMed Web of Science ®Google Scholar
• Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety and efficacy of Vagus Nerve Stimulation in treatment-resistant depression. A systematic review. J Affect Disord. 2008;110(1):1–15. doi:10.1016/j.jad.2008.02.01218374988
   PubMed Web of Science ®Google Scholar
• Lv H, Zhao Y-H, Chen J-G, Wang D-Y, Chen H. Vagus Nerve Stimulation for depression: a systematic review. Front Psychol. 2019;10:64. doi:10.3389/fpsyg.2019.0006430766497
   PubMed Web of Science ®Google Scholar
• Gaynes BN, Asher G, Gartlehner G, et al. Definition of treatment-resistant depression in the medicare population. AHRQ technology assessments; 2018 Available from: https://www.ncbi.nlm.nih.gov/pubmed/30260611. Accessed 1130, 2020.
   Google Scholar
• Centers for Medicare and Medicaid Services. Decision memo for vagus nerve stimulation for treatment of resistant depression (TRD) (CAG-00313R). CMS; 2019 Available from: https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=292. Accessed 1130, 2020.
   Google Scholar
• Conway CR, Olin B, Aaronson ST, et al. A prospective, multi-center randomized, controlled, blinded trial of vagus nerve stimulation for difficult to treat depression: a novel design for a novel treatment. Contemp Clin Trials. 2020;95:106066. doi:10.1016/j.cct.2020.10606632569757
   PubMed Web of Science ®Google Scholar
• Murrough JW, Iosifescu DV, Chang LC, et al. Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry. 2013;170(10):1134–1142. doi:10.1176/appi.ajp.2013.1303039223982301
   PubMed Web of Science ®Google Scholar
• Canuso CM, Singh JB, Fedgchin M, et al. Efficacy and safety of Intranasal esketamine for the rapid reduction of symptoms of depression and suicidality in patients at Imminent risk for suicide: results of a double-blind, randomized, placebo-controlled study. Am J Psychiatry. 2018;175(7):620–630. doi:10.1176/appi.ajp.2018.1706072029656663
   PubMed Web of Science ®Google Scholar
• Nobler MS, Sackeim HA, Moeller JR, Prudic J, Petkova E, Waternaux C. Quantifying the speed of symptomatic improvement with electroconvulsive therapy: comparison of alternative statistical methods. Convuls Ther. 1997;13(4):208–221.9437565
   PubMedGoogle Scholar
• Lapidus KA, Shin JS, Pasculli RM, Briggs MC, Popeo DM, Kellner CH. Low-dose right unilateral electroconvulsive therapy (ECT): effectiveness of the first treatment. J ECT. 2013;29(2):83–85. doi:10.1097/YCT.0b013e31827e0b5123449042
   PubMed Web of Science ®Google Scholar
• Machado-Vieira R, Baumann J, Wheeler-Castillo C, et al. The timing of antidepressant effects: a comparison of diverse pharmacological and somatic treatments. Pharmaceuticals (Basel, Switzerland). 2010;3(1):19–41. doi:10.3390/ph3010019
   Google Scholar
• Rodrigues FB, Duarte GS, Prescott D, Ferreira J, Costa J. Deep brain stimulation for dystonia. Cochrane Database Syst Rev. 2019;1:CD012405. doi:10.1002/14651858.CD012405.pub230629283
   PubMed Web of Science ®Google Scholar
• Vitek JL, Jain R, Chen L, et al. Subthalamic nucleus deep brain stimulation with a multiple independent constant current-controlled device in Parkinson’s disease (INTREPID): a multicentre, double-blind, randomised, sham-controlled study. Lancet Neurol. 2020;19(6):491–501. doi:10.1016/S1474-4422(20)30108-332470421
   PubMed Web of Science ®Google Scholar
• Salanova V, Witt T, Worth R, et al. Long-term efficacy and safety of thalamic stimulation for drug-resistant partial epilepsy. Neurology. 2015;84(10):1017–1025. doi:10.1212/WNL.000000000000133425663221
   PubMed Web of Science ®Google Scholar
• Fisher R, Salanova V, Witt T, et al. Electrical stimulation of the anterior nucleus of thalamus for treatment of refractory epilepsy. Epilepsia. 2010;51(5):899–908. doi:10.1111/j.1528-1167.2010.02536.x20331461
   PubMed Web of Science ®Google Scholar
• Schruers K, Baldi S, van den Heuvel T, et al. The effects of deep-brain non-stimulation in severe obsessive-compulsive disorder: an individual patient data meta-analysis. Transl Psychiatry. 2019;9(1):183. doi:10.1038/s41398-019-0522-631383848
   PubMed Web of Science ®Google Scholar
• Paykel ES. Remission and residual symptomatology in major depression. Psychopathology. 1998;31(1):5–14. doi:10.1159/0000290189500681
   PubMed Web of Science ®Google Scholar
• Paykel ES. Achieving gains beyond response. Acta Psychiatr Scand Suppl. 2002;415:12–17. doi:10.1034/j.1600-0447.106.s415.3.x
   Google Scholar
• Bloch MH, Green C, Kichuk SA, et al. Long-term outcome in adults with obsessive-compulsive disorder. Depress Anxiety. 2013;30(8):716–722. doi:10.1002/da.2210323532944
   PubMed Web of Science ®Google Scholar